Department of Radiation Oncology, Leuvens Kankerinstituut, University Hospitals Leuven, Campus Gasthuisberg, Leuven, Belgium.
Strahlenther Onkol. 2011 Jan;187(1):23-31. doi: 10.1007/s00066-010-2139-9. Epub 2010 Dec 22.
To retrospectively report the outcome of head and neck cancer patients following re-irradiation.
A total of 51 patients with recurrent or second primary head and neck cancer received re-irradiation at Leuven University Hospital. Survival and locoregional control were calculated. Doses to organs at risk were retrieved from dose-volume histograms. Radiation-related toxicities were reported.
The 2-year actuarial overall survival rate was 30%. On univariate analysis, surgery before re-irradiation and high radiation dose were associated with superior survival. Grade 3 acute and grade 3 or more late toxicity occurred in respectively 29.4% and 35.3% of the patients.
Re-irradiation in head and neck cancer patients is feasible with acceptable late toxicity, although the survival remains poor.
回顾性报告头颈部癌症患者接受再放疗的结果。
共有 51 例复发性或第二原发头颈部癌症患者在鲁汶大学医院接受再放疗。计算了生存率和局部区域控制率。从剂量-体积直方图中检索了危及器官的剂量。报告了与放射相关的毒性。
2 年总生存率为 30%。单因素分析显示，再放疗前手术和高剂量放疗与生存改善相关。分别有 29.4%和 35.3%的患者发生 3 级急性和 3 级或更高级别的迟发性毒性。
对头颈部癌症患者进行再放疗是可行的，且晚期毒性可接受，但生存仍然较差。
